Luke Halpern, Assistant Editor

The pharmaceutical giant will reportedly lower their drug prices to align with most favored nation status.

A hybrid chatbot that evaluates stages of change in pneumococcal vaccination desires while providing artificial intelligence (AI)-based Q&A opportunities improved uptake in older adults.

Ron Lanton advises pharmacies to maintain compliance, explore contingency options, and stay engaged with policymakers during the government shutdown.

As one of the most prescribed medications worldwide, proton pump inhibitor use could serve as a bulwark against severe outcomes in hospitalized adults with COVID-19.

A retrospective analysis found no associations between lipid parameters and the success of blood stem cell mobilization in a cohort of healthy donors.

Christian Ruff, MD, highlights pharmacists as essential clinical partners who help optimize drug selection, dosing, and safety for patients with complex needs.

Pharmacists’ accessibility and expertise make them essential allies for patients managing weight through medication, Donna Ryan explains.

Vaccination with 23-valent pneumococcal polysaccharide vaccine did not reduce the rates of acute coronary syndrome and ischemic stroke in a randomized clinical trial.

Craig Beavers discusses recent developments in hypertension management and the clinical implications of the Bax Hypertension and Cardia-3 trials with Shelby Tungate from the UNC Eshelman School of Pharmacy.

William Van Decker, MD, discusses the key priorities of the upcoming ACC Legislative Conference, including telehealth, cardiovascular rehab, prior authorization reform, and the role of pharmacists in shaping patient-centered cardiovascular policy.

Johnson & Johnson presented new long-term data of icotrokinra from ICONIC-LEAD, along with data from ICONIC-ADVANCE indicating head-to-head superiority with standard-of-care deucravacitinib.

New results from the phase 3 HYPERION trial demonstrate reduced risks as early as the year following diagnosis of pulmonary arterial hypertension.

Martha Thorne discusses the operational, financial, and patient care challenges pharmacies face under the 340B rebate pilot and the need for advocacy, automation, and transparency to sustain access.

The angiopoietin-like-3-targeting treatment received an expanded indication for individuals aged 1 through 5 years, building on earlier approvals in older populations.

Pulmonary fibrosis was observed in many patients with severe COVID-19 in a retrospective cohort study, indicating the need for more effective care and prevention.

For American Pharmacists Month, see how recent instances of conflicting medical advice show the importance of pharmacists as trustworthy health care professionals.

Investigators found inconsistencies across subgroups, but the overall efficacy and safety of pneumococcal vaccination was affirmed.

The approval was based on positive efficacy and safety indications from the IMforte clinical trial of patients with extensive-stage small cell lung cancer (SCLC).

The RNA interference therapy indicated that, along with its therapeutic benefits in cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM), there was a reduced risk of GI events.

In an announcement at the White House, Pfizer said it will reduce drug prices in the United States to match those of other countries.

AMT-130 demonstrates meaningful reductions in disease progression in the rare and chronic Huntington disease.

Pharmacists should ensure pneumococcal vaccination strategies are tailored to high-risk individuals, especially those with type 2 diabetes (T2D).

Inclisiran, a small interfering RNA PCSK9 inhibitor, was effective and tolerable in real-world practice, though pharmacists must make important considerations for patients switching from another medicine.

The new formulation of intravenous immunoglobulin (IVIG) provides patients another option to help reduce the incidence of severe bacterial infections.

A meta-analysis found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce sustained reductions across lipid biomarkers, including low-density lipoprotein cholesterol (LDL-C).

Young, non-diabetic individuals were most likely to delay statin initiation for low-density lipoprotein cholesterol (LDL-C) lowering, increasing their risk of myocardial infarction.

Individuals with heart failure who are Black, Hispanic, or Asian face a much earlier onset of heart failure hospitalization compared with White patients.

In a dose-escalation portion of LINKER-MM4, linvoseltamab monotherapy demonstrated a high overall response rate (ORR) and minimum residual disease (MRD) negativity in both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

Using the United States Vaccine Adverse Event Reporting System database, investigators found that pneumococcal vaccination led to predominantly nonserious adverse events.

Recent studies reveal that simvastatin does not enhance escitalopram's effects in treating depression, despite improving metabolic health in obese patients.